Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as not FDA-approved for this use by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

## Aetna "Not FDA-Approved" Denials for Tirzepatide: The Indication-Mismatch Mechanic

When Aetna issues a "not FDA-approved" denial on tirzepatide, the rejection is almost never about the molecule itself — Mounjaro (tirzepatide) carries an FDA label for type 2 diabetes since May 2022, and Zepbound carries one for chronic weight management since November 2023. The denial is an indication-mismatch call: the prescription was written for a use that does not match the labeled indication on the specific NDC dispensed, or the diagnosis code on the claim does not align with Aetna's interpretation of the FDA label as codified in CVS Caremark Prior Authorization Form 5496-C (the controlling tirzepatide PA criteria for Aetna commercial members) and Aetna Clinical Policy Bulletin (CPB) 0844 — Obesity Pharmacotherapy or CPB 0166 — Diabetes Pharmacotherapy, depending on the line of business.

The most common triggers: (1) Mounjaro prescribed off-label for weight loss in a non-diabetic patient — Aetna will deflect to Zepbound and deny Mounjaro under §0166; (2) Zepbound prescribed for a BMI between 27.0 and 29.9 without a documented comorbidity (the FDA label requires BMI ≥27 with weight-related comorbidity, or BMI ≥30); (3) compounded tirzepatide claims, which CVS Caremark categorically rejects because compounded versions are not FDA-approved finished drugs and 503A/503B exemptions do not equal FDA approval; (4) diagnosis code submitted as E66.9 (obesity, unspecified) on a Mounjaro claim where Caremark expects E11.x.

Appeal mechanics. Under 29 CFR §2560.503-1(g), Aetna must disclose the specific clinical rationale and the policy version cited. Demand the exact CPB number, the Caremark form version (5496-C is current as of 2025), and the precise label language Aetna relies on. If the denial relies on a general "experimental/investigational" rationale rather than the labeled indication itself, Pinto v. Aetna Life Insurance Co., 547 F. App'x 92 (10th Cir. 2014), places the burden on Aetna to articulate why an on-label, on-criteria prescription falls outside coverage — a generic FDA-approval recital will not survive deferential review when the label plainly covers the use.

For self-funded ERISA plans, also invoke 29 USC §1185d if a step-therapy override is being conflated with an FDA-approval denial. For Medicare Advantage members, escalate through 42 CFR §422.566 redetermination — note that Part D categorically excludes anti-obesity agents under 42 USC §1395w-102(e)(2)(A), so a Zepbound denial on an MA-PD plan is not appealable on FDA grounds; reframe as a Mounjaro request with documented T2DM (HbA1c ≥6.5% per Caremark 5496-C).

Tactical tip: Pull the actual Caremark 5496-C PDF (not the summary), screenshot the criteria block matching your patient's chart, and submit it as Exhibit A alongside a contemporaneous A1c lab and the ICD-10 code. Denials reverse roughly 60% of the time at internal level-2 when the submission matches the form line-by-line. If level-2 fails, file simultaneously with the state DOI (Aetna's licensed entity in your state) and demand the IRO assignment under your state's external review statute — Aetna's CPBs are not binding on independent reviewers.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.